Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

121. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for CrohnÔ??s disease

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for CrohnÔ??s disease A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease Dretzke J, Edlin R, Round J (...) , Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's

2011 Health Technology Assessment (HTA) Database.

122. Adalimumab in severe and acute sciatica: A multicentre, randomised, double-blind, placebo-controlled trial (Full text)

Adalimumab in severe and acute sciatica: A multicentre, randomised, double-blind, placebo-controlled trial Based on several experimental results and on a preliminary study, a trial was undertaken to assess the efficacy of adalimumab, a tumor necrosis factor alpha inhibitor, in patients with radicular pain due to lumbar disc herniation.A multicenter, double-blind, randomized controlled trial was conducted between May 2005 and December 2007 in Switzerland. Patients with acute (duration of <12 (...) weeks) and severe (Oswestry Disability Index score of >50) radicular leg pain and imaging-confirmed lumbar disc herniation were randomized to receive as adjuvant therapy either 2 subcutaneous injections of adalimumab (40 mg) at 7-day intervals or matching placebo. The primary outcome was the score for leg pain, based on a visual analog scale (0-100 mm), which was recorded every day for 10 days and at 6 weeks and 6 months.Of the 265 patients screened, 61 were enrolled; 31 patients were assigned

2010 EvidenceUpdates PubMed

123. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (PubMed)

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis To evaluate the efficacy and safety of using the anti-tumor necrosis factor-alpha (anti-TNF-alpha) drugs adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.Systematic review and meta-analysis of 21 randomized, placebo-controlled trials (eight adalimumab, seven infliximab, six etanercept).Adults with rheumatoid arthritis who received (...) adalimumab (1524 patients), infliximab (1116 patients), etanercept (1029 patients), or placebo (2834 patients) with or without concomitant methotrexate in all groups.A literature search of several databases from January 1995-December 2008 was performed. There were no restrictions based on language or date of publication, and low-quality studies (based on Jadad score) were excluded. American College of Rheumatology (ACR) 20% improvement criteria (ACR20), 50% improvement criteria (ACR50), and 70

2010 EvidenceUpdates

124. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial (Full text)

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial In early and active RA despite MTX, continuous treatment with TNF blockers in combination with MTX is recommended. To compare this strategy with an initial combination of MTX and adalimumab (ADA) given for 3 months and then adjusted based on the disease activity status.Prospective unblinded randomized multicentre

2010 EvidenceUpdates PubMed

125. Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease

Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Humira (Adalimumab) (Abbott Laboratories) for treatment

2010 Health Technology Assessment (HTA) Database.

126. Infliximab (review) and adalimumab for the treatment of Crohn's disease (TA187)

Infliximab (review) and adalimumab for the treatment of Crohn's disease (TA187) Overview | Infliximab and adalimumab for the treatment of Crohn's disease | Guidance | NICE Infliximab and adalimumab for the treatment of Crohn's disease Technology appraisal guidance [TA187] Published date: 19 May 2010 Share Save Guidance on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults. The recommendations also apply to biosimilar products of the technologies

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

127. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199) Overview | Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | Guidance | NICE Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Technology appraisal guidance [TA199] Published date: 25 August 2010 Share Guidance on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults (...) . The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication. This guidance replaces NICE technology appraisal guidance on: etanercept and infliximab for the treatment of psoriatic arthritis (TA104) and adalimumab for the treatment of psoriatic arthritis (TA125). Guidance development process Next review date: This guidance will be reviewed if there is new evidence. Your responsibility The recommendations

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

128. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195) Overview | Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | Guidance | NICE Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance [TA195 (...) ] Published date: 25 August 2010 Share Guidance on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough. The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

129. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis

A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

130. Adalimumab for the treatment of psoriasis (Full text)

Adalimumab for the treatment of psoriasis Adalimumab for the treatment of psoriasis Adalimumab for the treatment of psoriasis Turner D, Picot J, Cooper K, Loveman E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Turner D, Picot J, Cooper K, Loveman E. Adalimumab for the treatment of psoriasis. Health Technology Assessment 2009; 13 (Suppl (...) 2 Article 7): 49-54 Final publication URL Additional data URL Indexing Status Subject indexing assigned by NLM MeSH Adalimumab; Anti-Inflammatory Agents /economics /therapeutic use; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Cost-Benefit Analysiss; Psoriasis /drug therapy; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic Language Published English Country of organisation England English summary An English language

2009 Health Technology Assessment (HTA) Database. PubMed

131. Adalimumab (Humira) for Crohns Disease

Adalimumab (Humira) for Crohns Disease Adalimumab (Humira) for Crohns Disease Adalimumab (Humira) for Crohns Disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Adalimumab (Humira) for Crohns Disease . Lansdale: HAYES, Inc.. 2009 Authors' objectives Adalimumab (D2E7, Humira®; Abbott Laboratories) is a recombinant human

2009 Health Technology Assessment (HTA) Database.

132. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis (Full text)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) strategies were usual care, infliximab 5mg per kg with a switch to adalimumab if there was no response or if the response was lost during maintenance therapy, and infliximab 5mg per kg with a switch to 10mg per kg if there was no response and a switch to adalimumab if the response was lost during maintenance therapy. Both the infliximab and adalimumab strategies consisted of initial treatment at weeks zero, two, and six, followed by maintenance treatment every eight weeks. The usual care was conventional

2009 NHS Economic Evaluation Database. PubMed

133. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab

Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

134. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

135. Adalimumab - Psoriasis

Adalimumab - Psoriasis Common Drug Review CEDAC Meeting – September 17, 2008 Page 1 of 3 Notice of CEDAC Final Recommendation – October 16, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ADALIMUMAB (Humira ® – Abbott Laboratories Ltd.) NEW INDICATION: PSORIASIS Description: Adalimumab is a human monoclonal antibody tumour necrosis factor (TNF). The basis of this resubmission is a new indication. Adalimumab is indicated for the treatment of adult patients (...) with chronic moderate to severe psoriasis who are candidates for systemic therapy. For patients with chronic moderate plaque psoriasis, adalimumab should be used after phototherapy has been shown to be ineffective or inappropriate. Previous CEDAC Recommendations for Adalimumab: • Rheumatoid arthritis (see Notice of CEDAC Final Recommendation, February 11, 2005) • Psoriatic arthritis (see Notice of CEDAC Final Recommendation, November 29, 2006) • Ankylosing spondylitis (see Notice of CEDAC Final

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

136. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two (Full text)

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two To evaluate the efficacy and safety of the tumor necrosis factor (TNF) antagonist adalimumab in patients with axial spondylarthritis (SpA) without radiographically defined sacroiliitis refractory to conventional treatment.Patients with active axial SpA (...) (n = 46) were randomized to receive placebo or adalimumab at a dosage of 40 mg subcutaneously every other week for 12 weeks, followed by an open-label extension that continued up to week 52. The diagnosis of axial SpA required the presence of 3 of 6 diagnostic criteria, including 2 of the following 3 criteria: inflammatory back pain, HLA-B27 positivity, or acute inflammation of the spine or sacroiliac joints on magnetic resonance imaging, in the absence of radiographic evidence of sacroiliitis

2008 EvidenceUpdates PubMed

137. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial (PubMed)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis.We sought to evaluate clinical efficacy and safety of adalimumab for moderate to severe psoriasis and investigate continuous versus interrupted therapy.We conducted a 52-week, multicenter study of 1212 patients randomized to receive adalimumab (40 mg (...) ) or placebo every other week for the first 15 weeks. At least 75% improvement in the Psoriasis Area and Severity Index (PASI) score was the criterion for advancement through this multiphase study.At week 16, 71% (578 of 814) of adalimumab- and 7% (26 of 398) of placebo-treated patients achieved greater than or equal to 75% improvement in the PASI score. During weeks 33 to 52, the percentage of patients rerandomized to placebo who lost adequate response (defined as <50% improvement in the PASI response

2008 EvidenceUpdates

138. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. (PubMed)

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis.Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously received treatment with nonsteroidal antiinflammatory drugs underwent stratification (...) according to methotrexate use and received 24 mg of adalimumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other week for 16 weeks. We randomly assigned patients with an American College of Rheumatology Pediatric 30% (ACR Pedi 30) response at week 16 to receive adalimumab or placebo in a double-blind fashion every other week for up to 32 weeks.Seventy-four percent of patients not receiving methotrexate (64 of 86) and 94% of those receiving methotrexate (80 of 85) had

2008 NEJM

139. Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease

Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease Article Text

2008 Evidence-Based Medicine (Requires free registration)

140. Adalimumab - Crohn's disease

Adalimumab - Crohn's disease Common Drug Review CEDAC Meeting – November 21, 2007 Page 1 of 3 Notice of CEDAC Final Recommendation – December 19, 2007 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ADALIMUMAB RESUBMISSION #3 (Humira ® – Abbott Laboratories Ltd.) Description: Adalimumab is a human monoclonal antibody to tumour necrosis factor (TNF). The Canadian Expert Drug Advisory Committee (CEDAC) previously reviewed adalimumab for rheumatoid arthritis (see CEDAC Final (...) Recommendation on Adalimumab, February 11, 2005), psoriatic arthritis (see CEDAC Final Recommendation, November 29, 2006) and ankylosing spondylitis (see CEDAC Final Recommendation, June 27, 2007). A new indication for use in Crohn’s disease was the basis for this resubmission. Adalimumab is approved for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderate to severely active Crohn’s disease who have had an inadequate response to conventional therapy

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review